Oron Yacoby Zeevi, DVM, PhDImmunobel Therapeutics における Chief Scientific Officerスピーカー
プロフィール
Over 30 years of extensive experience in leading scientific research and drug development programs of small molecules and biologicals for the treatment and management of various disease indications. VP R&D and CSO at Neuroderm until it was acquired in 2017 by Mitsubishi Tanabe in one of the largest deals in the biotech field in Israel ($1.1 billion), and later as CSO of Neurosense Therapeutics (NASDAQ). Involved in advising start-up companies and investors in the biotech field. Inventor of over 80 issued patents and pending patent applications.